Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 548 Market St. #49404 SAN FRANCISCO CA 94101 |
Tel: | N/A |
Website: | https://www.bettertx.com |
IR: | See website |
Key People | ||
Craig R. Jalbert President, Chief Executive Officer, Treasurer, Company Secretary, Director |
Business Overview |
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients. |
Financial Overview |
For the nine months ended 30 September 2023, Better Therapeutics Inc revenues was not reported. Net loss decreased 26% to $22.8M. Lower net loss reflects Research and development - Balancing val decrease of 46% to $7M (expense), General and administrative - Balancing v decrease of 24% to $7.9M (expense), Stock-based Compensation in SG decrease of 19% to $721K (expense). |
Employees: | 54 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $7.71M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$26.50M as of Sep 30, 2023 |
Net annual income (TTM): | -$31.57M as of Sep 30, 2023 |
Free cash flow (TTM): | -$27.40M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $7.71M as of Sep 30, 2023 |
Shares outstanding: | 49,861,726 as of Dec 1, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |